SCHEMBL27848619

SCHEMBL27848619

Cc1c(NN)cc(-c2ccccc2)cc1C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 2/20 0.48
▸ RAB9A P51151 2/20 0.48
▸ PTPN1 P18031 3/20 0.46
▸ AKR1C2 P52895 3/20 0.45
▸ AKR1C1 Q04828 3/20 0.45
▸ AKR1C4 P17516 1/20 0.45
▸ AKR1C3 P42330 1/20 0.45
▸ ACMSD Q8TDX5 2/20 0.45
▸ MCL1 Q07820 2/20 0.45
▸ DHFR P00374 1/20 0.45
▸ HNF4A P41235 1/20 0.45
▸ PTPN2 P17706 1/20 0.44
▸ PTPN6 P29350 1/20 0.44
▸ ACLY P53396 3/20 0.44
▸ DHODH Q02127 1/20 0.43
▸ FTO Q9C0B1 2/20 0.43
▸ FABP4 P15090 1/20 0.43
▸ PTGER4 P35408 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.42
▸ CASP3 P42574 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27786187 0.82 PTPN1 (0.58) PTPN1AKR1C2AKR1C1AKR1C4AKR1C3
SCHEMBL27879335 0.80 NPC1 (0.66) NPC1RAB9AACLYDHODHHDAC3
SCHEMBL27863059 0.79 NPC1 (0.47) NPC1RAB9APTPN1AKR1C2AKR1C1
SCHEMBL27846422 0.78 KMT2A (0.59) PTPN1AKR1C2AKR1C1AKR1C4AKR1C3
SCHEMBL14784538 0.78 PTPN1 (0.53) PTPN1AKR1C2AKR1C1AKR1C4AKR1C3
SCHEMBL28794195 0.77 PTGS1 (0.64) PTPN1PTPN2PTPN6KDM4EHDAC3
SCHEMBL3467831 0.76 PTPN1 (0.51) PTPN1AKR1C2AKR1C1AKR1C4AKR1C3
SCHEMBL28794193 0.76 HDAC1 (0.41) PTPN1KDM4EHSD17B10HDAC3HDAC1
SCHEMBL27827712 0.75 PTPN1 (0.50) NPC1RAB9APTPN1AKR1C2AKR1C1
SCHEMBL23645564 0.73 PTPN1 (0.48) PTPN1AKR1C2AKR1C1AKR1C4AKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101903359-B Triazole-substituted arylamide derivatives and their use as P2X3 and/or P2X2/3 purinergic receptor antagonists HOFFMANN LA ROCHE 2013-05-22 — — CN disclosed
CN-101903359-A Triazole-substituted arylamide derivatives and their use as P2X3And/or P2X2/3Use of purinergic receptor antagonists HOFFMANN LA ROCHE 2010-12-01 — — CN disclosed
Send feedback